Michael Tanen

4.3k citations
21 papers · 2.2k · 1 hit paper · h-index 14

Impact in

Papers in

  • Physiology 9
    • Alzheimer's disease research and treatments 5
    • Adipose Tissue and Metabolism 3
  • Molecular Biology 8
    • Peroxisome Proliferator-Activated Receptors 4
    • Retinoids in leukemia and cellular processes 3
Co-authors
Joel P. Berger (4 shared papers)David E. Moller (4 shared papers)Karen Snyder (5 shared papers)Gary Herman (3 shared papers)Wesley Tanaka (3 shared papers)Arthur Bergman (3 shared papers)Bingming Yi (2 shared papers)John A. Wagner (5 shared papers)
Journals
Alzheimer s & Dementia (4 papers)Molecular Endocrinology (2 papers)Clinical Pharmacology & Therapeutics (2 papers)Journal of Biological Chemistry (2 papers)Journal of Alzheimer s Disease (1 paper)
Partner nations
United StatesUnited KingdomNetherlands

In The Last Decade

Michael Tanen

21 papers receiving 2.1k citations

Michael Tanen's Hit Papers

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization 2002 · 511 citations
5110+8+16Years since publication100200300400500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2002 Endocrinology

Peers

Michael Tanen
Comparison fields: 5 of 96
  • Endocrinology, Diabetes and Metabolism 851
  • Physiology 587
  • Endocrine and Autonomic Systems 115
  • Pharmacology 242
  • Epidemiology 407
Replace Hiroyuki Odaka with:
Hiroyuki Odaka Japan
Nobuo Sakamoto Japan
James R. Paterniti United States
Michael Mark Germany
Clemens Fürnsinn Austria
Hirofumi Misu Japan
Philippe Poulain France
Yukio Shigeta Japan
Randy L. Webb United States
J.C. Fruchart France
Michael Tanen relative to Hiroyuki Odaka Japan Hiroyuki Odaka's profile →
Citations per field
00.5×1.7×
Hiroyuki Odaka · 1×
Citations per year

Countries citing papers authored by Michael Tanen

Since Specialization
Citations

This map shows the geographic impact of Michael Tanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Tanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Tanen more than expected).

Fields of papers citing papers by Michael Tanen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Tanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Tanen. The network helps show where Michael Tanen may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Tanen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Tanen Line = papers co-authored together Michael Tanen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization
Endocrinology ·Terry P. Combs, John A. Wagner, Joel P. Berger, Tom Doebber, Wenjun Wang, Bei B. Zhang, Michael Tanen, Anders H. Berg, Stephen O’Rahilly, David B. Savage, Krishna Chatterjee, Stuart Weiss, Patrick Larson, Keith Gottesdiener, Barry J. Gertz, Maureen Charron, Philipp E. Scherer, David E. Moller
Hit paper breakdown →		2002511
2
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
Clinical Pharmacology & Therapeutics ·Gary Herman, C. Melinda Stevens, Koen Vandyck, Arthur Bergman, Bingming Yi, M DESMET, Karen Snyder, D Hilliard, Michael Tanen, Wesley Tanaka
2005435
3
Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein γ Selective Modulator
Molecular Endocrinology ·Joel P. Berger, Ann Petro, Karen L. MacNaul, Linda J Kelly, Bei B. Zhang, Karen Richards, Alex Elbrecht, Bruce A. Johnson, Gaochao Zhou, Thomas W. Doebber, Chhabi Biswas, Mona Parikh, Neelam Sharma, Michael Tanen, G M Thompson, John Ventre, Alan D. Adams, Ralph Mosley, Richard S. Surwit, David E. Moller
2003283
4
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
Clinical Therapeutics ·Arthur Bergman, Catherine Stevens, Yanyan Zhou, Bingming Yi, Martine E. Laethem, Marina De Smet, Karen Snyder, Deborah Hilliard, Wesley Tanaka, Wei Zeng, Michael Tanen, Amy Q. Wang, Li Chen, Gregory A. Winchell, Michael J. Davies, Steven Ramael, John A. Wagner, Gary Herman
2006223
5
Peroxisome Proliferator-activated Receptor-γ Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity
Journal of Biological Chemistry ·Joel P. Berger, Michael Tanen, Alex Elbrecht, Anne Hermanowski‐Vosatka, David E. Moller, Samuel D. Wright, Rolf Thieringer
2001178
6
Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects
The Journal of Clinical Pharmacology ·Gary Herman, Arthur Bergman, Fang Liu, Cathy Stevens, Amy Q. Wang, Wei Zeng, Li Chen, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka, Alan G. Meehan, Kenneth C. Lasseter, Stacy C. Dilzer, Robert A. Blum, John A. Wagner
2006150
7
Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons
Brain Research ·John Woods, Michael Tanen, David J. Figueroa, Chhabi Biswas, Emanuel Zycband, David E. Moller, Christopher P. Austin, Joel P. Berger
200399
8
Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort
Journal of Alzheimer s Disease ·Jeffrey L. Seeburger, Daniel Holder, Marc Combrinck, Catharine Joachim, Omar Laterza, Michael Tanen, Aimée Dallob, Derek L Chappell, Karen Snyder, Mary Flynn, Adam Simon, Vijay Modur, William Z. Potter, Gordon Wilcock, Mary J. Savage, A. David Smith
201566
9
Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry
Clinical Chemistry ·Thomas McAvoy, Michael E. Lassman, Daniel S. Spellman, Zhenlian Ke, Bonnie J. Howell, Oitak Wong, Zhu Lan, Michael Tanen, Arie Struyk, Omar Laterza
201460
10
Transcriptional Silencing by Unliganded Thyroid Hormone Receptor β Requires a Soluble Corepressor That Interacts with the Ligand-Binding Domain of the Receptor
Molecular and Cellular Biology ·Guo‐Xia Tong, M. Jeyakumar, Michael Tanen, Milan K. Bagchi
199643
11
Ligand Modulates the Interaction of Thyroid Hormone Receptor β with the Basal Transcription Machinery
Journal of Biological Chemistry ·Guo‐Xia Tong, Michael Tanen, Milan K. Bagchi
199542
12
P4‐196: The novel BACE inhibitor MK‐8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single‐ and multiple‐dose administration
Alzheimer s & Dementia ·Mark S. Forman, John Palcza, Jack Tseng, J. Leempoels, Steven Ramael, David Han, Stanford S. Jhee, Larry Ereshefsky, Michael Tanen, Omar Laterza, Marissa F. Dockendorf, Gopal Krishna, Lei Ma, John A. Wagner, Matthew D. Troyer
201241
13
Analysis of the Functional Role of Steroid Receptor Coactivator-1 in Ligand-Induced Transactivation by Thyroid Hormone Receptor
Molecular Endocrinology ·M. Jeyakumar, Michael Tanen, Milan K. Bagchi
199740
14
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study
Clinical Pharmacology & Therapeutics ·K. Chris Min, Marissa F. Dockendorf, John Palcza, Jack Tseng, Lei Ma, Julie A. Stone, Huub Jan Kleijn, Peter Hodsman, Kazuko Masuo, Michael Tanen, Matthew D. Troyer, Marianne van Vugt, Mark S. Forman
201818
15
Evaluation of Urinary Renal Biomarkers for Early Prediction of Acute Kidney Injury Following Partial Nephrectomy: A Feasibility Study
European Urology Focus ·Brian R. Lane, Stephen K. Babitz, Kateřina Vlasáková, Allen Wong, Sabrina L. Noyes, William Boshoven, Pam Grady, Cindy Zimmerman, Susan Engerman, Maureen Gebben, Michael Tanen, Warren E. Glaab, Frank D. Sistare
201813
16
Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen
European Clinical Respiratory Journal ·Rob Zuiker, Marcella Ruddy, Nicoletta Morelli, Robin Mogg, Veronica M. Rivas, Kristien Van Dyck, Inge De Lepeleire, Michael Tanen, J. D. Boot, Ingrid M. C. Kamerling, Zuzana Diamant
201511
17
Next Generation Ligand Binding Assays—Review of Emerging Real-Time Measurement Technologies
The AAPS Journal ·Stephanie Fraser, Mark J. Cameron, Edward O’Connor, Martin Schwickart, Michael Tanen, Mark Ware
20146
18
O4–05–05: Consistency of BACE inhibitor‐mediated brain amyloid production inhibition by MK‐8931 in Alzheimer's disease patients and healthy young adults
Alzheimer s & Dementia ·Julie A. Stone, Huub Jan Kleijn, Marissa F. Dockendorf, Lei Ma, John Palcza, Jack Tseng, Michael Tanen, Mark S. Forman
20136
19
P1‐225: A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK‐8931 in Japanese subjects
Alzheimer s & Dementia ·K. Chris Min, Mark S. Forman, Marissa F. Dockendorf, John Palcza, Peter Soni, Lei Ma, Gopal Krishna, Peter Hodsman, Kazuko Masuo, Michael Tanen, John A. Wagner, Matthew D. Troyer
20123
20
Detection Of Increased Levels Of Th2-derived Cytokines In Ultracentrifuged Sputum Following Allergen Challenge And Their Responsiveness To Fluticasone
Marcella Ruddy, Rob Zuiker, Nicoletta Morelli, Robin Mogg, Verónica Rivas, Kristien Van Dyck, Inge De Lepeleire, Michael Tanen, A Pica-Mendez, Zuzana Diamant
20102

About Michael Tanen

Michael Tanen is a scholar working on Physiology, Molecular Biology, Endocrinology, Diabetes and Metabolism, Immunology and Pharmacology, having authored 21 papers that have together received 2.2k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (5 papers), Peroxisome Proliferator-Activated Receptors (4 papers), Estrogen and related hormone effects (3 papers), Cholinesterase and Neurodegenerative Diseases (3 papers), Retinoids in leukemia and cellular processes (3 papers), Diabetes Treatment and Management (3 papers), Computational Drug Discovery Methods (3 papers) and Adipose Tissue and Metabolism (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (851 citations), Physiology (587 citations), Endocrine and Autonomic Systems (115 citations), Pharmacology (242 citations) and Epidemiology (407 citations). Michael Tanen has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Joel P. Berger, David E. Moller, Karen Snyder, Gary Herman, Wesley Tanaka, Arthur Bergman, Bingming Yi, John A. Wagner, D Hilliard and C. Melinda Stevens. Their work appears in journals such as Alzheimer s & Dementia, Molecular Endocrinology, Clinical Pharmacology & Therapeutics, Journal of Biological Chemistry and Journal of Alzheimer s Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroyuki OdakaBreakdown of academic impact, for papers by Nobuo SakamotoBreakdown of academic impact, for papers by James R. PaternitiBreakdown of academic impact, for papers by Michael MarkBreakdown of academic impact, for papers by Clemens FürnsinnBreakdown of academic impact, for papers by Hirofumi MisuBreakdown of academic impact, for papers by Philippe PoulainBreakdown of academic impact, for papers by Yukio ShigetaBreakdown of academic impact, for papers by Randy L. WebbBreakdown of academic impact, for papers by J.C. Fruchart